Dr. Douville has 20 years experience in senior leadership positions in the biopharma industry. He is the founder of Milestone Pharmaceuticals and currently serves as the company’s Chief Scientific Officer. Prior to his role as CSO, Dr. Douville was the Chief Executive Officer from 2005 to 2017. As CEO, he raised a total of $34 million in several rounds of equity financing with leading life sciences venture capital firms to lead Milestone’s etripamil program from paper concept through to the end of Phase 2 and assemble a world-class development team around the program.
Dr. Douville has served as a Director on Milestone’s Board of Directors since its inception in 2005 and was Chairman from 2011 to 2012.
Prior to Milestone, he held the positions of CEO and Chief Business Officer at Galileo Genomics (later Genizon Biosciences), a population genomics company he co-founded. As the founding CEO of Galileo, he negotiated a seminal strategic alliance with Myriad Genetics that provided the company’s initial funding and subsequently, as Chief Business Officer; he was instrumental in preparing the company for its Series A financing. Dr. Douville obtained his Ph.D. in Neuroscience from McGill University (Canada) in 1991 and later pursued several years of post-doctoral research activities at the University of Zurich (Switzerland). He later received an MBA from the HEC at the University of Montreal in 1997.